Disclaimer. Dialogue with a Patient 3/18/2016

Similar documents
WHO, WHAT, WHEN AND WHERE OF PARKINSON S DIAGNOSIS. MJFF Third Thursdays Webinar March 17, 2016

GDUFA: 2 ½ years later Impact & Importance

Other EU Activities Contributing to Harmonization of Labeling

THE MICHAEL J. FOX FOUNDATION FOR PARKINSON S RESEARCH. Funding Opportunities

Preview of New MedDRA Hierarchy for Medication Errors Coding and Retrieval Considerations

SPEAKING UP ABOUT OFF PERIODS

Web-based epro: Validation, Equivalence, and Data Quality. Brian Tiplady

Data retrieval using the new SMQ Medication Errors

Business Plan. Fujitsu and Macmillan Cancer Support

Healthcare Professional Information & Patient Information Leaflet (PL)

3/31/2009. Phase 0 Microdosing Studies with Renin Inhibitors. Disclaimer. Overview of Today s Presentation. J. Chris Jensen Consultant

So, My FitBit is Clinical Trial Grade Right? Keith Wenzel Senior Director, Solution Incubator PAREXEL International

Regulatory scientific significance of Japan s ADR relief system

The Telemetric and Holter ECG Warehouse (THEW) Initiative

Disclaimer. Statistical Aspects of Revision of CHMP Bioequivalence Guidelines. David Brown MHRA

9/20/2011. Impact of EU Paediatric Regulation on drug development and Marketing authorisations Industry experience

Program Agenda. 11:45 AM ET Registrants Join the Program Dial-in: (877) Log-in:

CHAPTER GUIDELINES Contents: Updated: Fall 2017

Regulatory Experience in Reviewing CV Safety for Diabetes

Designing patient-centered clinical trials: Results of the MDIC project to use patient preference information to design clinical trials

Disclaimer. The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be

MJFF S VISION FOR PARTNERING WITH PATIENTS. Sohini Chowdhury The Michael J. Fox Foundation

2017 Phoenix Clinical Research Fair Program of Events

Optimizing Clinical Communication in Parkinson s Disease:

PMDA Perspectives on Oncology Panel. REIKO YANAGIHARA, Ph.D. Office of In Vitro Diagnostics PMDA

Conducting Observational studies in Latin America: Academia, Ethical Committees & Pharmaceutic Industry

To find a cure for Parkinson s

Global Pediatric Development: We Are Making Progress. PMDA Perspective. Junko Sato, PhD PMDA

YEARS & COUNTING Annual Report

Centralized Procedure

Since 1982, NPF has funded more than $155 million in research and support services.

DIA Oligonucleotide-Based Therapeutics Conference

MedDRA Coding Quality: How to Avoid Common Pitfalls

PSYCHIATRY. THE POWER OFx. Experts. Experience. Execution. A Deeper Dive into Psychiatry. Scientifically-Driven Clinical Development

The PD You Don t See: Cognitive and Non-motor Symptoms

TRAUMA RECOVERY/HAP OPERATING GUIDELINES

SPOTLIGHT ON MOVEMENT FUNCTION: COPING WITH ON/OFF PERIODS WELCOME AND INTRODUCTIONS

WELCOME. Parkinson s 101 for the Newly Diagnosed. Today s Topic: Parkinson s Basics presented by Cari Friedman, LCSW

6 Opportunities for Improving Pathways to Market: A Global Perspective on Dementia

Non-motor subtypes of Early Parkinson Disease in the Parkinson s Progression Markers Initiative

DVD. Inside. Featuring Michael J. Fox

Supportive Neurology: Valuing Increased Function and Improved QoL in Treatment of Non-Core Symptoms of Neurological Disease

Sponsorship & Hosting Opportunities. Connect with our family enterprise community Canada s largest and most influential industry segment

The PD You Don t See: Cognitive and Non-motor Symptoms

annual report

Trauma xviv7.3-png COMMOOIES Of age* tlietotirt. Memorandum of Understanding. between. American Red Cross San Diego Imperial Counties Chapter.

Electrocardiographic Markers Associated with Sotalol-induced Torsades de Pointes

APDA Tulsa Optimism Walk 2018 Sponsorship Proposal

A Million Hands. Social Action Partnership September 2019 to July 2022

The Foundation for a Drug-Free World presents. 10th Anniversary DRUG-FREE HEROS. Awards Gala

2016 Programs & Information

Cognitive Impairment - Parkinson's Disease Foundation (PDF)

INTRODUCTION TO FOX TRIAL FINDER. Accelerating Clinical Trial Recruitment Online

A NATIONAL AFRICAN AMERICAN BREAST CANCER SURVIVORSHIP ORGANIZATION. Celebrating. Survivorship

OCTOBER EOEA and the Alzheimer s Association have organized implementation of the plan around its five major recommendations:

Peer Networks 101. The Role of a Statewide Network 07/31/2018. Cameron Wood, CRPS-A Executive Director Peer Support Coalition of Florida, Inc.

Headway Victoria Epilepsy and Parkinson s Centre

RARE DISEASE DAY INFORMATION PACK 28 FEBRUARY 2017 PATIENT INVOLVEMENT: RESEARCH JOIN THE INTERNATIONAL CAMPAIGN TO RAISE AWARENESS FOR RARE DISEASES

Part I Parkinson Disease Diagnosis and Treatment

Unmet needs. in Parkinson s research

Data-Driven Study Feasibility Assessment and Impact on Successful Execution of Clinical Trial Protocols

Parkinson s Research Program

Food can serve as a non pharmacological control in thorough cardiac safety studies

Reshaping the Enrollment Strategy: Creating a Health Management Program That Sustains Employee Engagement

Deep Brain Stimulation: Indications and Ethical Applications

SUPPORT FEDERAL FUNDING FOR PARKINSON S DISEASE RESEARCH AND DRUG DEVELOPMENT

National Alzheimer s project U.S.

FOCUS ON. Diversity & Inclusion

Patient-Centered Endpoints in Oncology

APDA Oklahoma Optimism Walk 2017 Sponsorship Proposal

AWARDS GALA PRESENTED BY THE FOUNDATION FOR A DRUG-FREE WORLD

FOR RESERVATIONS, VISIT OUR WEBSITE AT

SOUTH DAKOTA TEAM HOPE WALK/5K & 10K

USING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE. The Michael J. Fox Foundation for Parkinson s Research

HUNTINGTON S DISEASE AWARENESS MONTH MAY 2018 CAMPAIGN TOOLKIT.

Welcome and Introductions

EXPLORING OPPORTUNITIES TO PARTNER TOWARD CURES FOR PD. Chicago Clinical Research Fair June 11, 2016

Section II: Board of Director Nominee Information *Full Name (Last, First) Laverdure, Michael Richard Lee

Civitan International Research Center Achievements

SPONSORSHIP OPPORTUNITIES

CDNF: Finnish academia-industry collaboration for unique clinical study in Parkinson s disease

ANNUAL REPORT PLANNED PARENTHOOD PASADENA AND SAN GABRIEL VALLEY THANK YOU FOR YOUR SUPPORT!

10th Medicine Review Course st July Prakash Kumar

Parkinson s Disease Clinical Practice Guideline

2019 ORANGE COUNTY HEROES LUNCHEON

ANIMAL MODELS OF PARKINSON S DISEASE: STATE OF THE FIELD & THE FUTURE! KULDIP DAVE

2/14/2018. Rounding the Bases: Hitting a Home Run on Lawyer Wellness. Presented by: What is Addiction?

NEUROSCIENCE. THE POWER OFx. Experts. Experience. Execution. A Deeper Dive into Neurology. Scientifically-Driven Clinical Development

What are the Latest Treatment Advances in Parkinson disease

Multiple System Atrophy

Down Syndrome Association of Atlanta Position Description

Parkinson s Disease AGE 50, ALTHOUGH IT SOMETIMES OCCURS IN YOUNGER ADULTS. PARKINSON S DISEASE MOST OFTEN DEVELOPS AFTER

Northwestern University. Consent Form and HIPAA Authorization for Research

10/27/2011. Challenges in Anti-diabetic Global Drug Development A Shift from Surrogate to Outcome Trials. Disclaimer

Sponsorship Opportunity 51 st Annual Keep Texas Beautiful Conference Georgetown, TX June 11-13, 2018

COUNCIL. Executive Committee. President Jan Lerut, MD, PhD. President-Elect Michael Charlton, MD. Secretary John R.

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Dementia: It s Not Always Alzheimer s

Discover science with Fine Science Tools. shipping globally since 1974 FINE SURGICAL INSTRUMENTS FOR RESEARCH

Welcome to today s webinar

Transcription:

Medical Affairs and Scientific Communications 2016 Annual Forum Dialogue with a Patient Bill Wilkins, Co-Founder, Executive Director, Wilkins Parkinsons Foundation March 21-23 Kissimmee, FL Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organization with which the presenter is employed or affiliated. These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, DIA and DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners. 2015 DIA, Inc. All rights reserved. 1

BIO» Diagnosed with PD in 2006» Co-Founder, Wilkins Parkinson s Foundation» Charter member, The Michael J. Fox Foundation Patient Council Other relevant info:» Founded PD Friends group in 2007» Instituted pro-bono APDA GA Chapter media campaign in 2007» First-annual Polo for Parkinson s fundraising event in 2008» Recipient of Michael J. Fox Foundation s MVP award in 2009» MJFF digital & billboard media program in 2009-2010» Co-Founded Wilkins Parkinson s Foundation in 2010» Charter member of MJFF Patient Council in 2010» Appointed to Emory Udall Community Outreach Board in 2011» Received Wesley Woods Key to a Cure award in 2012» Provided discounted & pro bono media support to Unity Walk 2011 2015» Atlanta Presenting Partner for MJFF/Abbvie Partners in Parkinson s in 2014» Organizing partner of Parkinson s Disease Southern Symposium in 2014» Recipient of Alan Bonander Humanitarian Award in 2015 3 WHAT IS PARKINSON S DISEASE? Parkinson s is a chronic, degenerative neurological disorder for which there is no known cure. Vital Stats Today, an estimated 1M people in the United States and more than 5M worldwide are living with Parkinson s disease (PD) PD is the second most common brain disease after Alzheimer s One in 100 people over the age of 60 have PD, although some are diagnosed at 40 or younger The exact cause of PD is unknown, although researchers point to a combination of genetic and environmental factors 4 2

THE MANY FACES OF PARKINSON S DISEASE YouTube video: https://www.youtube.com/watch?edit=vd&v=kqhfojmt05o With permission: Fox Foundation 2016 5 PARKINSON S DISEASE (PD) IS HIGHLY VARIABLE AND IDIOSYNCRATIC PD is a boutique disease it is unique to each individual living with it People are usually more familiar with the motor symptoms of PD, as these are the signs of disease that are most noticeable from the outside. Some cardinal motor symptoms of PD include: Resting tremor Slowness of movement Rigidity Issues with gait and balance Doctors are increasingly recognizing the presence and effects of PD s nonmotor symptoms, which include: Cognitive dysfunction Depression and anxiety Constipation and digestion issues Sleep disorders Loss of Smell 6 3

CURRENT UNMET NEEDS IN PD Disease Modifying Therapies» There is no therapy that can prevent, slow or halt the progression of PD Improved Symptomatic Therapies» Today s best PD drug was discovered in 1967 (when Lyndon B. Johnson was president). PD patients need therapies to better address disease symptoms, including: Freezing of gait Some patients suffer from gait problems that can stop them in their tracks and increase their risk of falls Swallowing problems A decrease in the ability to swallow normally is a non-motor symptom of PD Biomarkers» There is currently no validated biomarker of PD. This means: There s no objective way to diagnose PD, leading to high rates of misdiagnosis There s no way to identify people at risk for PD or establish strategies for prevention There s no way to objectively measure the effectiveness of experimental treatments in clinical trials without a progression marker to track disease 7 HOW PATIENT S CAN BEST MANAGE THEIR DISEASE OVER TIME Because Build a comprehensive people with PD care can team live long and productive lives with the treatments currently available Because on the PD market, involves disease a wide range management of symptoms, is of working the utmost with a importance. variety of health care providers (physical therapist, nutritionist, etc.) is beneficial Participate in research Clinical trials are a crucial step on the path to developing better treatments for PD patients today, and yet 85% of trials face delays because of a lack of volunteers, resulting in a dramatic slowdown in progress toward a cure Maintain health and wellness Diet and exercise are an essential part of healthy living for PD patients Engage with the community Getting educating on your disease, building a supportive care network, and taking advantage of the many national and local resources available to PD patients are all important steps toward living well with PD 8 4

Ask 5